SCHEMBL23645166

SCHEMBL23645166

CC(C)CC(NC(=O)CNC(=O)c1cc(F)ccc1Br)OB(O)O

nearest known ligand 0.57

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
PSMB5 P28074 11/20 0.57
PSMB8 P28062 8/20 0.57
PSMB9 P28065 8/20 0.57
PSMB6 P28072 8/20 0.57
PSMB10 P40306 8/20 0.57
PSMB11 A5LHX3 7/20 0.57
PSMA7 O14818 7/20 0.57
PSMB1 P20618 7/20 0.57
PSMA1 P25786 7/20 0.57
PSMA2 P25787 7/20 0.57
PSMA3 P25788 7/20 0.57
PSMA4 P25789 7/20 0.57
PSMA5 P28066 7/20 0.57
PSMB4 P28070 7/20 0.57
PSMB3 P49720 7/20 0.57
PSMB2 P49721 7/20 0.57
PSMA6 P60900 7/20 0.57
PSMA8 Q8TAA3 7/20 0.57
PSMB7 Q99436 7/20 0.57
NFKB1 P19838 1/20 0.43

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL30529994 0.89 PSMB5 (0.71) PSMB5PSMB8PSMB9PSMB6PSMB10
SCHEMBL10005021 0.89 PSMB5 (0.71) PSMB5PSMB8PSMB9PSMB6PSMB10
SCHEMBL10004622 0.88 PSMB5 (0.58) PSMB5PSMB8PSMB9PSMB6PSMB10
SCHEMBL21977971 0.88 PSMB5 (0.58) PSMB5PSMB8PSMB9PSMB6PSMB10
SCHEMBL10005139 0.87 PSMB5 (0.59) PSMB5PSMB8PSMB9PSMB6PSMB10
SCHEMBL10004915 0.86 PSMB5 (0.55) PSMB5PSMB8PSMB9PSMB6PSMB10
SCHEMBL17667669 0.85 PSMB5 (0.53) PSMB5PSMB8PSMB9PSMB6PSMB10
SCHEMBL21841192 0.84 PSMB5 (0.80) PSMB5PSMB8PSMB9PSMB6PSMB10
SCHEMBL23645176 0.83 PSMB5 (0.57) PSMB5PSMB8PSMB9PSMB6PSMB10
SCHEMBL30529995 0.83 PSMB5 (0.57) PSMB5PSMB8PSMB9PSMB6PSMB10

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-12157749-B2 Borate-based drug and use thereof CHENGDU ORIGIN BIOTECHNOLOGY LIMITED COMPANY (CN) 2024-12-03 US disclosed
EP-3851108-B1 BORATE-BASED DRUG AND USE THEREOF CHENGDU ORIGIN BIOTECHNOLOGY LTD COMPANY (CN) 2023-08-09 EP disclosed
US-20210332069-A1 Borate-Based Drug And Use Thereof CHENGDU ORIGIN BIOTECHNOLOGY LIMITED COMPANY (CN) 2021-10-28 US disclosed
EP-3851108-A1 BORATE-BASED DRUG AND USE THEREOF Chengdu Origin Biotechnology Limited Company (CN) 2021-07-21 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20210332069-A1 Borate-Based Drug And Use Thereof PSMB11, PSMB1, PSMB3 PSMB5 8/4885PSMB8 11/4885PSMB9 18/4885
US-12157749-B2 Borate-based drug and use thereof PSMB11, PSMB1, PSMB3 PSMB5 8/4885PSMB8 11/4885PSMB9 18/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.